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Abstract
Background: The importance of a complete resection of high‑grade gliomas (HGGs) 
has been highlighted in scientific literature, in order to limit tumor recurrence and 
above all to improve disease‑free survival rates. Several fluorescent biomarkers 
have been tested to improve intraoperative identification of residual tumor; 
5‑aminolevulinic acid (5‑ALA) and fluorescein sodium (FS) are now starting to 
play a central role in glioma surgery. We performed a retrospective analysis on 
47 patients operated for HGGs. Here we report our preliminary data.
Methods: Data of 47 consecutive patients with HGG have been collected in 
our study (25 males, 22 females; mean age: 60.3 years, range: 27–86 years). 
Fluorescein (5 mg/kg of body weight) was injected intravenously right after the 
induction of general anesthesia. A YELLOW 560 filter was used on an OPMI 
Pentero 900 microscope (Carl Zeiss Meditec, Oberkochen, Germany) to complete 
a microsurgical tumor removal. Glioma resection and quality of life were evaluated 
preoperative and postoperatively.
Results: Gross total resection (GTR) was achieved in 53.2% (n = 25) of patients. 
A subtotal resection (STR) (>95%) was achieved in 29.8% (n = 14), while a partial 
resection (PR) (<95%) was obtained in 17% (n = 8) of patients. Overall, in 83% 
(n = 39) of patients who underwent fluorescence‑guided surgery the resection rate 
achieved was >95%. No adverse effects correlated to fluorescein have been recorded.
Conclusion: Fluorescein seems to be safe and effective in the resection of HGGs, 
allowing a high rate of gross total removal of contrast enhanced areas.
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INTRODUCTION
Gliomas are the most common primary malignant 
brain tumors in adults, nearly represent 80%, with 
poor prognosis in their high‑grade forms.[24] According 
to the current WHO grading system, high grades 
include grade III and IV lesions. One‑year survival 
rate for high‑grade gliomas (HGGs) is 53.7%, while 
2‑year survival rate for these patients is only 14.6%.[8] 
Annually, 8,000 new cases are diagnosed in the United 
States.[18,20] Several variables positively affect the 
prognosis for patients diagnosed with HGG: these 
include young age, tumor location, radiological features, 
recurrence, and the opportunity to perform an adjuvant 
therapy in the postoperative course.[34] Recent studies 
identified a strong correlation between removal extent 
of glioblastomas and overall survival with maximal 
survival benefit when resection volume is greater than 
98% and surgery is followed by adjuvant radiotherapy 
and chemotherapy.[9,19,29,36] Unfortunately, the similarity 
between tumor appearance and surrounding brain 
parenchyma under the operating microscope makes a 
complete tumor resection challenging.[20] In recent years, 
fluorescence‑guided technology has started to emerge 
in glioma resection procedures to help the surgeon 
differentiating intraoperatively neoplastic tissue from 
normal brain in order to maximize the extent of glioma 
resection. Several fluorescent biomarkers have been 
investigated to improve intraoperative identification 
of residual tumor: 5‑aminolevulinic acid (5‑ALA) and 
fluorescein sodium (FS) are the most promising in glioma 
surgery.[38] 5‑ALA, metabolized by some tumoral cell 
enzymes into the strongly fluorescent protoporphyrin IX, 
has been used as a metabolic marker in glioma surgery 
with good results.[9,11] Although its 100% specificity and 
a 85% sensitivity for tumoral tissues,[27] several elements 
have limited the widespread of 5‑ALA fluorescence to 
guide gliomas resection: first of all its high costs (more 
than 900 euros for each vial), but also the way of 
administration (oral, some hours before the induction 
of anesthesia) and the high risk of skin sensitization 
within 24 h after the operation (the patient should not 
be exposed to sunlight or strong artificial light).[3] On 
the contrary, FS is a fluorescent substance that can be 
used for immediate improved visualization of brain 
tumor tissue, with nonspecificity for tumor cells.[27] 
This dye, if excited by a light whose wavelength is in 
the range of 460–500 nm, emits fluorescent radiation 
with wavelength range of 540–690 nm. FS does not 
selectively accumulate in astrocytoma cells, but in 
extracellular tumor sites, suggesting its role as a marker 
for compromised blood‑brain barrier (BBB) areas, as in 
high‑grade astrocytomas. Widely used in ophthalmic 
surgery, fluorescein is injected intravenously just before 
glioma resection, it is virtually free of side effects and 
has low costs, approximately 5 euros each vial (1 g of 
substance).[3,30] It is usually visible to the naked eye at 
high dosage (20 mg/kg body weight) and at lower doses, 
it is observable under the YELLOW 560 nm surgical 
microscope filter, allowing a better tissue discrimination 
with more natural colors [Table 1].[10,32] In this study, we 
report our preliminary data retrospectively collected on 
47 patients operated for HGGs. Our aim is to demonstrate 
the effectiveness and safety of fluorescence‑guided 
surgery in HGG surgery. We focus on histology, tumor 
removal rate, clinical pre‑ and postoperative parameters, 
quality of life, and any adverse effects.[27]
MATERIALS AND METHODS
In this retrospective study, after the approval of 
Local Ethic Committee, we collected data of 
47 patients (25 males, 22 females; mean age: 60.3 years, 
range: 27–86 years). All patients had been surgically 
treated at the Neurosurgical Unit of ARNAS Civico 
Hospital, between September 2015 and November 
2016 [Table 2]. Each patient was informed on benefits 
and risks connected with the study and all of them 
signed an informed consent. The inclusion criteria were 
as follows: 1) age between 18 years and 90 years; 2) 
suspect of HGG (astrocytoma III or IV grade according 
WHO classification) on the basis of contrast enhanced 
magnetic resonance imaging (MRI) findings; 3) tumor 
location that allowed a complete surgical resection of the 
enhanced area (i.e., no eloquent areas). Exclusion criteria 
were as follows: 1) severe heart, liver or kidney disease; 2) 
recent acute ischemic stroke; 3) prior history of adverse 
reaction to FS or severe reactions to other contrast agents; 
4) women during the first trimester of pregnancy; 5) 
specific neural tumor locations such as corpus callosum, 
basal ganglia, brain stem, posterior cranial fossa; 6) 
preoperative KPS (Karnofsky Performance Status) score 
of 60 or less; 7) tumor diameter <1 cm or >5 cm; 8) 
history of non‑neural malignant tumors.
Surgical protocol
In all cases 5 mg/kg body weight of FS was injected 
intravenously via the central venous line, after the 
induction of anesthesia. Vital signs were monitored for 
15 min. Under white light, no fluorescent effect was 
detected. The fluorescent dye was visible under the 
Table 1: Brief comparison between 5‑aminolevulinic acid 





Working area brightness Dark Optimal
Cost Elevated Moderate
Safety Skin sensitization Virtually free of side effects
5-ALA: 5-aminolevulinic acid, FS: Fluorescein sodium
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YELLOW 560 nm filter, on the OPMI Pentero 900 surgical 
microscope (Carl Zeiss Meditec, Oberkochen, Germany). 
The fluorescence shaped the vital tumor margins 
[Figure 1]. All the procedures were carried out by the 
same senior neurosurgeon (N.F.); this allowed distinction 
between cases in which fluorescence was judged “helpful” 
and cases in which was considered “not helpful”, on the 
basis of a clear intraoperative distinction between the 
normal brain and the tumor tissue. Neuronavigation was 
used for tumor localization, mostly for the localization 
of close eloquent areas. Autologous fibrin glue was used 
as sealant when necessary.[12,13,22,23] Postoperatively, all the 
patients were admitted in the neurosurgical intensive 
care unit (ICU) for postoperative care.
Pre‑ and postoperative clinical assessment
Each patient general physical performance was recorded 
using the KPS. The median preoperative KPS score was 
85.1 (range: 70–100). Preoperative clinical evaluation 
was performed at the admission to the neurosurgical 
unit. A second evaluation was conducted during the 
postoperative course, on discharge and at the first 
outpatient clinic visit approximately 1 month later. The 
neurological exam was evaluated by a neurologist. Surgery 
was followed by radiotherapy with concomitant and 
adjuvant temozolomide in 85.1% of cases, according to 
the Stupp protocol.[37]
Radiological assessment
Postoperatively, the extent of tumor resection was 
identified by 35 contrast enhanced T1 weighted MRI and 
12 contrast enhanced computed tomography (CT scan), 
72 h after surgery. Three categories were distinguished: 
no residual tumor tissue = gross total resection (GTR); 
minimal residual tumor tissue = subtotal resection (STR) 
and partial resection (PR). GTR was defined as 
resection where no residual enhanced tumor is visible, 
STR was defined as nearly total (>95%), PR as <95%. 
Postoperative tumor volumes after surgery were calculated 
using an open‑source, free medical image viewer 
software (OsiriX for Mac) on enhanced residual tissue (in 
T1 weighted MRI or CT scan) [Figures 2 and 3].
Histological examination
Histological analyses were performed with standard 
procedures. The classification was conducted on the 
basis of the current WHO classification of tumors of the 
central nervous system.
RESULTS
The average duration of the surgical procedure (“skin to 
skin”) was 175.5 min (range: 108–316 min); the median 
length of hospital stay was 20 days (range: 8–73 days). 
Patients and tumor data and results are summarized in 
Tables 2 and 3. At neuropathological analysis, 14 patients 
were diagnosed with anaplastic astrocytoma grade III, 
while 33 patients were diagnosed with a grade IV 
glioblastoma, according to the WHO classification. No 
adverse effects associated with the administration of 
FS were observed. Yellow staining of sclera, skin, and 
Table 2: Demographic data and presenting 
characteristic of the patients
Characteristic Number of patients (%)
Total number of patients 47 (100)

























KPS: Karnofsky Performance Status
Figure 1: Intraoperative view of a right frontal glioblastoma under 
normal white xenon‑light illumination (a) and at the beginning of 
tumor removal under the YELLOW 560 nm filter (b). During tumor 
removal on the Pentero 900 surgical microscope, there is a clear 
delineation of the tumor area which shows significant fluorescein 
sodium enhancement revealing the boundary between the bright 
yellow tumor and the surrounding brain (c); at the end of the 
removal, no residual tumor tissue is evident (d)
a b
c d
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urine disappeared within approximately 24 h after the 
surgical procedure. No abnormal changes have been 
observed in routine blood or urine examinations, nor in 
liver and kidney function tests. All tumors effectively 
stained yellow with FS during the surgical procedure. The 
senior neurosurgeon (N.F.) judged the use of YELLOW 
560 nm filter, together with a low dose of FS as “helpful” 
in all cases. The resection extent was evaluated by two 
neurosurgeons and two neuroradiologists, by analyzing 
postoperative neuroimaging exams performed within 
72 h after surgery (35 enhanced MRI, 12 enhanced 
CT scans). GTR was achieved in 53.2% (n = 25) of 
patients. A STR (>95%) was achieved in 29.8% (n = 14) 
of them, while a PR (<95%) was obtained in 
17% (n = 8) of patients. Globally, a >95% resection was 
achieved in 83% (n = 39) of patients who underwent 
fluorescence‑guided surgery. The median postoperative 
KPS score was 83.4 (range: 50–100). Postoperative score 
was higher for 15 patients, lower for 11, and was the 
same as the preoperative one for 21 patients. Overall, 
eight serious complications emerged: six postoperative 
brain hemorrhages, one sepsis, and one hydrocephalus. 
In fifteen patients, new motor deficits were observed 
after surgery, nine of which were transient paresis, 
which resolved completely within 1 month. In four 
patients seizures occurred postoperatively. There was no 
perioperative mortality. The overall median follow‑up was 
10.2 months (range: 3–18 months).
DISCUSSION
The importance of radical resection in glioma surgery has 
been already stressed in literature. Although rare cases of 
spontaneous regression of benign tumors after incomplete 
removal are described,[35] radical resection of malignant 
Figure 2: Preoperative neuroimaging of a right frontal glioblastoma. Gadolinium enhanced T1 weighted brain magnetic resonance 
imaging (MRI)
Figure 3: Postoperative neuroimaging of a right frontal glioblastoma. Gadolinium enhanced T1 weighted brain magnetic resonance 
imaging (MRI)
Table 3: Summary of the results of this observational study
Characteristic Number of patients (%)
Mean surgical procedure duration (min) 175.5 (range: 108‑316)















GTR: Gross total resection, STR: Subtotal resection, PR: Partial resection
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tumor allows long‑term survival.[15] Thus, the need for 
radical surgery in brain tumor is becoming a main stone 
of the modern neurosurgical philosophy. For this purpose, 
different technological excellences have been used in the 
operating theatres, as the new generation intraoperative 
neuroradiological assessment devices.[6] The use of 
fluorescent markers during surgical procedures to dye 
tumor tissue has become an important tool in neoplastic 
resection. Although the role of intraoperative contrast 
enhancement is well described in the literature, mainly 
for vascular diseases,[5] such a technique is progressively 
gaining more consent as a modern armamentarium to 
achieve radical removal. FS is a fluorophore, that has 
been used in medical applications for more than six 
decades.[25] This dye penetrates in those areas of the 
brain where the BBB is damaged, allowing real time 
enhancement of the areas enlightened by gadolinium in 
MRI. In experimental studies, a rodent BBB disruption 
with intra‑arterial mannitol administration has been 
demonstrated to enhance fluorescein signal in the 
brain.[21] The fluorescence of FS can be grossly perceived 
to the naked eye, when this agent is injected at high 
doses (20 mg/kg). However, when using a recent developed 
microscope integrated YELLOW 560 module (Carl Zeiss 
Meditec, Oberkochen, Germany), we can employ a low 
dose of FS (5 mg/kg) to detect an optimal fluorescence 
within the tumoral tissue.[28] From the analysis of the 
literature [Table 4], it emerges that, besides its wide 
and safe use in ophthalmology,[20] fluorescein injection 
seems to be a good method to obtain a high rate of 
GTR during malignant brain tumors surgery.[26] The 
percentage of resection in the series that we have 
analyzed varied from 75% to 100%.[4] In 2003, Shinoda 
et al.  reported a series of 32 patients surgically treated 
for glioblastoma multiforme. In 84.4% of these patients, 
gross total removal was obtained with a high dose of FS 
(20 mg/kg body weight). Only 30.1% obtained it with 
conventional white light imaging; no difference in the 
overall prognosis was observed in this series.[33] In 2008 
Koc et al. reported a prospective nonrandomized study 
to evaluate the influence of FS‑guided glioma resection 
on the extent of gross total tumor removal (GTR), 
overall prognosis, and side effects. Fourty‑seven out of 
the 80 patients enrolled, received a high dose (20 mg/
kg body weight) of intravenous FS after craniotomy. 
A standard operating room microscope without a filter or 
special camera was used. A second group of 33 patients 
underwent ordinary resections. The results showed a 
significant increase in the number of patients with 
GTR (83% vs. 55%) when fluorescein was administered. 
It was observed no statistically significant difference in 
overall survival between the two groups (44 weeks vs. 
42 weeks).[16,20] In 2012 Chen, in a cohort of 22 patients 
with HGGs, observed a significant improvement in 
progression‑free survival, together with the GTR rate, in 
patients treated with the aid of intraoperative intravenous 
injection of FS (15–20 mg/kg body weight) compared 
to the control group’s progression‑free survival.[8] In the 
same year, Okuda reported the safety and the efficacy 
of a new technique of fluorescence‑guided surgery for 
GBM surgery based on high dose FS with excitation and 
barrier filters on the operating microscope (OME‑9000 
Olympus). This new technique was employed in a series 
of 10 patients, enabling a detailed tumor assessment 
and allowing the identification of tumor vessels and 
surrounding normal vessels. This dye allowed to perform 
the surgical removal with both fluorescence and under 
normal white xenon‑light illumination.[27] After the 
study of Kuroiwa, who was the first to describe a novel 
technique of integration of the fluorescence filter in 
the microscope (Zeiss),[17] Schebesch in 2013 published 
data about a series of 35 patients with malignant brain 
tumor (whose 22 WHO HGGs) surgically treated with 
the aid of a reduced dose (3–4 mg/kg) of FS and with 
an intraoperative PENTERO 900 microscope equipped 
with the 560‑nm wavelength fluorescence light filter. 
In all cases, the tissue fluorescence was brightly visible 
30 min after administration of FS and it lasted for 
the entire duration of the procedure, representing a 
significant and “helpful” mean for the surgeon in 28 out 
of 35 cases.[31] Finally, Acerbi et al. was the first group 
to initiate a prospective phase II trial (FLUOGLIO) in 
20 consecutive patients with HGGs. In these patients, 
FS was administered intravenously at the induction of 
anesthesia. In this case, the fluorescence visualization 
during the surgical procedure was obtained with BLUE 
400 or YELLOW 560 filters on a PENTERO 900 
microscope at a very low dose (10 mg/kg with the BLUE 
400 filter and at 5 mg/kg with the YELLOW 560 filter). 
Data revealed a complete resection of the tumor in 80% 
of patients, a 6‑months progression‑free survival rate 
for 71.4%; moreover, a median survival of 11 months 
and a median duration of follow‑up of 10 months 
were shown.[1‑4] In February 2016, Hamamcıoğlu et al. 
presented their series of 23 high‑grade tumors and 
seven metastatic tumors treated with the intraoperative 
aid of 200 mg (2–4 mg/kg) of FS. This dye was found 
Table 4: Clinical series of patients with high‑grade 
gliomas treated with a fluorescein sodium aided surgery. 
Literature review
Study No. of HGG 
patients
FS dose Gross total 
removal (%)
Shinoda et al. 2003[33] 32 20 mg/kg 84.4%
Koc et al. 2008[16] 47 20 mg/kg 83%
Chen et al. 2012[8] 22 20 mg/kg 80%
Okuda et al. 2012[27] 10 20 mg/kg 50%
Schebesch et al. 2013[31] 35 3‑4 mg/kg 80%
Acerbi et al. 2013[3] 20 5 mg/kg 80%
Hamamcıoğlu et al. 2016[14] 23 2‑4 mg/kg 79%
FS: Fluorescein sodium
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“helpful” for tumor demarcation in 29 out of 30 
operations (97%). In 23 of these 29 operations (79%), a 
total resection (radiologically demonstrated) was achieved 
regardless of the histopathology, whereas a near‑total 
resection was achieved in four patients (14%). A STR was 
achieved in the remaining two patients (7%).[14]
In our experience, the use of FS together with 
YELLOW 560 nm filter has been found “helpful” in 
tumor removal in all the surgical procedures, allowing a 
better visual discrimination between the pinkish brain 
tissue and the yellow stained tumor tissue. This also 
seemed to be more comfortable to the surgeon eyes. 
The enhancement of tumoral tissue, which corresponds 
to the contrast enhancement of preoperative MRI, was 
visible immediately after dural opening, usually 30 min 
after the FS administration, and lasted until the end of 
tumor removal. The rate of tumor removal in our study 
was similar to that of previous studies. GTR was achieved 
in 53.2% (n = 25) of patients. A STR (>95%) was 
achieved in 29.8% (n = 14) of them, while a PR (<95%) 
was obtained in 17% (n = 8) of patients. Globally, a 
resection >95% was achieved in 83% (n = 39) of patients 
who underwent fluorescence‑guided surgery. Moreover, 
FS seemed to be safe and effective in the intraoperative 
visual phase by distinguishing tumor from normal 
brain tissue and in the postoperative neuroimaging 
control. The resection was also maximized with the 
aid of neuronavigation system in eloquent areas, trying 
to avoid additional neurological deficit to the patient. 
The median postoperative KPS score was 83.4 (range: 
50–100). Comparing pre‑ and postoperative scores, 
the latter was found higher in 15 patients, lower in 11, 
and stable in 21 patients. As in Schebesch, Acerbi, and 
Hamamcıoğlu series, we also report the use of low dose 
FS about 2 mL (5 mg/kg body weight). This low dose, 
together with YELLOW 560 nm filter, allowed an easier 
intraoperative management than higher doses of FS or 
5‑ALA, without the need to wait for the dye peak.[3,14,31] 
Although widely accepted in several fields of medicine 
as a very safe molecule, side effects of fluorescein 
administration, as skin reactions, syncope, respiratory or 
cardiac adverse effects, and seizures have been reported, 
but none of them occurred in this series.[17] Except for 
an expected and transitional change of skin color, sclera, 
and urine, which became slightly yellow (this effect 
disappeared completely within 24 h after fluorescein 
administration) none of the patients complained about 
any systemic or local side effect.[31] Although still limited 
by the small number of cases and by the absence of a 
control group of patients undergoing surgery without 
fluorescein (which we admit not to be a secondary 
aspect), our results are promising. It is clear that the use 
of intravenous fluorescein during the surgical removal of 
HGGs with a specific yellow filter, may be a very effective, 
safe, and inexpensive way to achieve a gross total removal 
of the tumor.[7] The cost of one application of 5‑ALA is 
approximately 200 times higher than one administration 
of FS (approximately 980€ and 5€, respectively).[30] 
The use of specific filters on surgical microscope allows 
an optimal delineation of tumoral tissue, assuring the 
visualization of the fluorescent areas, and distinguishing 
them from the peritumoral brain parenchyma and from 
vessels, which appear of “more natural” colors.[4] It should 
be emphasized that fluorescence technology shows 
BBB breakdowns, corresponding to the areas marked by 
the contrast agent in MRI. Consequently, a resection 
based on FS fluorescence, allows the removal of those 
neural tissue portions in which the BBB is interrupted. 
It does not necessarily allow resection of the full extent 
of infiltrating tumor cells, thus potentially reducing the 
accuracy of tumor identification. Moreover, the necrotic 
portion of the tumor does not stain with fluorescein, due 
to its lack of cerebral vasculature.[2,10]
CONCLUSIONS
The intraoperative identification and resection of HGGs 
is a significant and important challenge in neurosurgery. 
In our series fluorescence‑guided surgery of HGGs 
using FS has been a good tool in achieving GTR and 
in distinguishing tumoral by normal brain tissue. 
Larger‑scale studies are now needed, to quantify the 
efficacy of fluorescein‑guided surgery in improving the 
extent of resection as well as the progression‑free and 
overall patient survival.
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